OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
πΊπΈUnited States
International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2016-01-21
- Target Recruit Count
- 111
- Registration Number
- NCT02449044
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2024-10-10
- Target Recruit Count
- 1197
- Registration Number
- NCT02446132
- Locations
- πΊπΈ
Collier Neurologic Specialists, LLC, Naples, Florida, United States
πΊπΈNaples Research, Inc, Naples, Florida, United States
πΊπΈBayside Clinical Research Site #556, New Port Richey, Florida, United States
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2023-02-13
- Target Recruit Count
- 387
- Registration Number
- NCT02442765
- Locations
- π΅π·
Clinical Research Site, San Juan, Puerto Rico
πͺπͺClinical Research Site#2, Tallinn, Estonia
πͺπͺClinical Research Site#1, Tallinn, Estonia
A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2022-09-09
- Target Recruit Count
- 522
- Registration Number
- NCT02442778
- Locations
- πΊπΈ
Texas Neurology, P.A., Dallas, Texas, United States
πΊπΈBaylor College of Medicine, Houston, Texas, United States
πΊπΈHouston Methodist Neurological Institute, Houston, Texas, United States
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2015-09-21
- Target Recruit Count
- 631
- Registration Number
- NCT02435836
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2017-02-15
- Target Recruit Count
- 40
- Registration Number
- NCT02411695
Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2018-08-03
- Target Recruit Count
- 30
- Registration Number
- NCT02404532
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2019-11-27
- Target Recruit Count
- 1803
- Registration Number
- NCT02251275
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2018-08-15
- Target Recruit Count
- 67
- Registration Number
- NCT02219009
Β© Copyright 2024. All Rights Reserved by MedPath